Replies to post #2888 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

Enanta Pharmaceuticals PATENTS new compounds for HBV and HDV - MARCH 9, 2024

Thanks Steve. So in the not so distant future, EDP-514 might get a new friend in the battle against HBV. I just checked the ENTA web site and there was nothing there yet about the new patents but I will keep monitoring.

[DewDiligence]

Background—HDV infection is essentially a subtype of HBV infection that comprises the most intractable cases. The most advanced programs for HDV are GILD’s Hepludex and VIR’s VIR-3434/VIR-2218 combination. Hepludex is approved in the EU but not in the US, where GILD received a CRL in 2022 (#msg-170307133); VIR’s combination is in phase-2.